Fundamentals-based quality & risk · not a recommendation
Raw blend 46 capped to 40 by a red flag.
Raw blend 46 → capped to 40
Ind-Swift Laboratories Ltd scores 40/100 (Caution) on the Orion Score — weak business quality (38), poor growth (24), strong balance-sheet safety (73) and fair valuation (59). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
79/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹169.79 | ₹15.11 | 7.3% | ₹1.76 |
| Q3 2026 | ₹150.85 | ₹9.54 | -3.1% | ₹1.13 |
| Q2 2026 | ₹152.64 | ₹7.99 | -3.6% | ₹0.96 |
| Q4 2025 | ₹142.37 | ₹222.27 | -8.3% | ₹31.24 |
| Q3 2025 | ₹128.8 | ₹-5.49 | -9.7% | ₹-0.82 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2026 | ₹641.29 | ₹41.42 | ₹3,110.84 | 2.3% |
| FY 2025 | ₹574.24 | ₹250.48 | ₹285.2 | -5.5% |
| FY 2024 | ₹1,709.15 | ₹538.75 | ₹776.43 | 14.2% |
| FY 2023 | ₹1,207.31 | ₹47.6 | ₹230.28 | 15.0% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| INDSWFTLAB ★ | ₹1,374 Cr | 32.71 | 1.02% | 3.24% | 0.01x | 7.33% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹90,029 Cr | 25.94 | 12.55% | 9.93% | 0.21x | 15.11% |
| ABBOTINDIA | ₹57,724 Cr | 36.63 | 36.14% | 34.46% | 0.04x | 27.01% |
| AJANTPHARM | ₹41,836 Cr | 39.55 | 27.99% | 25.39% | 0.06x | 51.40% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹1,438.34 | ₹1,460.43 | ₹1,824.06 | ₹1,800.79 |
| Equity | ₹1,173 | ₹812.08 | ₹681.93 | ₹600.97 |
| Total Debt | ₹40.86 | ₹216.8 | ₹862.1 | ₹953.02 |
| Cash | ₹412.04 | ₹477.81 | ₹18.2 | ₹21.48 |
| Net Debt | — | — | ₹843.34 | ₹931 |
| Working Capital | ₹644.77 | ₹526.49 | ₹793.43 | ₹740.87 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 66.37% ↑ | 2.54% ↓ | 2.08% ↑ | 29.01% ↓ |
| Q3 FY2026 | 39.49% | 14.33% ↓ | 0.68% | 45.5% ↑ |
| Q2 FY2026 | 39.49% ↓ | 14.8% ↑ | 0.68% ↓ | 45.02% ↓ |
| Q1 FY2026 | 40.94% | 4.27% ↑ | 0.91% | 53.88% ↓ |
| Q4 FY2025 | 40.94% ↓ | 3.07% ↑ | 0.91% ↓ | 55.08% ↓ |
| Q3 FY2025 | 42.01% | 0.46% ↓ | 0.94% | 56.61% ↑ |
| Q2 FY2025 | 42.01% | 0.65% ↓ | 0.94% | 56.41% ↑ |
| Q1 FY2025 | 42.01% | 1.27% | 0.94% | 55.81% |
No recent corporate actions
Ask: "Is Ind-Swift Laboratories Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Ind-Swift Laboratories Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE915B01019. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.